Introduction
The v-ErbB oncogene is related in structure to the epidermal growth factor receptor (EGF-R) McMahon et al., 1991; Navolanic et al., 2003) . v-ErbB lacks most of the external ligand binding domain; however, it is constitutively activated and delivers a growth signal in the absence of ligand (McMahon et al., 1991; Navolanic et al., 2003) . The vErbB oncogene was initially discovered in the genome of avian erythroblastosis virus (AEV) and is the viral homologue of one of the first cellular oncogenes discovered, c-ErbB (Weiss et al., 1984) . v-ErbB will abrogate the requirement of erythroid progenitor cells for erythropoietin and stem cell factor (SCF) and block terminal differentiation (von Lindern et al., 2001) . Overexpression of the EGF-R has been observed in many pathological situations (Navolanic et al., 2003) . The EGF-R gene is amplified in certain tumors and this genetic abnormality is associated with malignancy. In certain human tumors (e.g. gliomas), there is a truncated form of the EGF-R referred to as EGFvIII, which is activated and resembles v-ErbB in its biological properties (Kuan et al., 2001) . Elucidating the mechanisms of EGF-R-mediated signal transduction will increase our understanding of how deregulated signaling can result in malignant transformation.
The proliferation of many hematopoietic precursor cells is promoted by interleukin-3 (IL-3), granulocyte/ macrophage colony-stimulating factor (GM-CSF), SCF (a.k.a., c-Kit-L) and Flt-3L (the ligand for the tyrosine kinase receptors Flt-2 and Flt-3 (Blalock et al., 1999; Chang et al., 2002; Lee and McCubrey, 2002) . IL-3 and GM-CSF exert their biological activity by binding to the IL-3 and GM-CSF receptors, respectively (Kitamura et al., 1991; Sato et al., 1993; Ihle et al., 1995; Pritchard et al., 1995; Steelman et al., 1996; Blalock et al., 1999; McCubrey et al., 2000) . These receptors are comprised of a ligand-specific a-subunit, and a common b-subunit (b c ), which is essential for signal transduction (Kitamura et al., 1991; Sato et al., 1993; Ihle et al., 1995; Pritchard et al., 1995; Steelman et al., 1996; Blalock et al., 1999; McCubrey et al., 2000) . After receptor ligation, the Shc protein becomes phosphorylated and forms a complex with the receptor (Larson et al., 2003; Steelman et al., 2004) . Shc then recruits the Grb2/Sos complex to the b c chain, which subsequently results in Ras activation, leading to the stimulation of Raf and MEK and mobilization of the MAP (ERK) kinase cascade (Bosch et al., 1997; Blalock et al., 1999 Blalock et al., , 2000a Blalock et al., , b, 2001 Chang et al., 2003b, c) . Receptor activation also creates a docking site on the receptor for phosphatidylinositol 3-kinase (PI3K), which phosphorylates certain membrane lipids in the cell membrane. The phospholipids recruit certain kinases via their pleckstrin (PH) homology domains including phosphoinositol-dependent kinase (PDK) and Akt. PDK phosphorylates and activates Akt, a key kinase that regulates many proteins involved in the control of apoptosis (Blalock et al., 1999; Chang et al., 2003a) .
In the following study, the effects of a conditional v-ErbB construct on the morphological transformation of NIH-3T3 cells and the factor dependence of hematopoietic cell lines were investigated. These studies used a novel v-ErbB:ER construct where its effects on growth and prevention of apoptosis could be directly measured. v-ErbB activity was required for the morphological transformation of NIH-3T3 cells and abrogation of cytokine dependence as these cells reverted to their nontransformed and cytokine-dependent states upon removal of b-estradiol or 4-OH tamoxifen (4HT). Understanding how deregulated v-ErbB expression activates signaling pathways and prevents apoptosis will further our comprehension of this critical pathway in normal and neoplastic cell growth.
Results

Hormone-dependent transformation by conditionally active v-ErbB:ER
Transduction of chicken c-Erb-B/EGFR into AEV ES-4 led to the generation of a constitutively active, oncogenic form of the protein, v-ErbB. The AEV ES-4 v-ErbB protein differs from c-ErbB/EGFR by a 584 amino-acid N-terminal deletion, a 73 amino-acid C-terminal deletion and a 21 amino-acid internal deletion (Figure 1 ). To generate a conditionally active form of v-ErbB, DNA sequences encoding v-ErbB ES-4 were fused in frame to the sequences encoding the hormone binding domain of the human estrogen receptor (hbER) to generate v-ErbB:ER. The strategy used to generate v-ErbB:ER led to the further loss of 11 amino acids from the C-terminus of v-ErbB. Sequences encoding v-ErbB were subcloned into a series of replication-defective retrovirus vectors for expression in mammalian cells McMahon et al., 1991; McMahon, 2001) . MLV-based vectors expressing ErbB were originally described as having the capacity to transform fibroblasts (NIH-3T3 and Rat1) and certain hematopoeitic cell lines Miller et al., 1990; McMahon et al., 1991) . In separate, but unpublished experiments conducted by Dr Arthur Bruskin and JM Bishop in 1986, a deletion mutant of ErbB truncated at the same EcoRI site used to make ErbB:ER was uncompromised in fibroblast-transforming potential. Moreover, the experiments described below clearly demonstrate that the removal of 11 amino acids from the C-terminus of ErbB-ES4 that occurred in the construction of ErbB:ER did not compromise the ability of this oncogene to transform fibroblastic and hematopoietic cells in a hormone-dependent manner.
To test for hormone-dependent oncogenic transformation, v-ErbB:ER was expressed in NIH-3T3 cells (named NIH-3T3/v-ErbB:ER), a cell line permissive for v-ErbB transformation McMahon et al., 1991) . NIH-3T3/v-ErbB:ER cells were treated with b-estradiol, 4HT or ethanol as a solvent control. Ethanol-treated cells had a normal flattened, nonrefractile cell morphology and displayed contact inhibition of growth ( Figure 2, panel a) . In contrast, addition of b-estradiol or 4HT (panels b and c) for 16-24 h resulted in cells displaying a rounded, refractile morphology with abundant dendritic processes and a loss of contact inhibition.
NIH-3T3/v-ErbB:ER cells were also cultured, at initially lower cell densities, for 2 weeks in the presence of b-estradiol in phenol red free medium containing charcoal-stripped (CS) fetal bovine serum (FBS). Under these conditions, the NIH-3T3/v-ErbB:ER cells formed foci of cells consistent with the morphological transformation (panel d), whereas in the absence of b-estradiol these foci were not present. The elevated foci of cells (Fan et al., 2002) .
Expression of the 97 kDa v-ErbB:ER chimera was assessed by Western blotting cell extracts from control (Neo) or v-ErbB:ER-expressing cells that were treated with ethanol, b-estradiol or 4HT for 16 h prior to preparation of cell extracts ( Figure 3, panel a) . Extracts of cells expressing the 69 kDa DRaf-1:ER protein were used a positive control (Samuels et al., 1993) . The expression of v-ErbB:ER was readily detected in ethanol-treated cells; however, the addition of bestradiol or 4HT led to the appearance of forms of vErbB:ER with reduced mobility. The v-ErbB:ER protein did not display the same extent of hormonedependent stabilization as that observed with DRaf-1:ER (Samuels et al., 1993) .
The species of v-ErbB:ER with reduced mobility observed after hormone addition are most likely not dimers, since this gel was run under reducing/denaturing conditions such that dimers should not survive the sample preparation. Since addition of hormone to cells expressing v-ErbB:ER leads to induced tyrosine phosphorylation of the fusion protein (see below), it seems highly likely that the species of v-ErbB:ER with reduced mobility observed after hormone addition are a consequence of phosphorylation. The mechanism of conditional activation of v-ErbB:ER most likely reflects hormone-dependent dimerization in intact cells. The major hormone-dependent dimerization domain in the ER is contained within the hormone binding domain and this domain displays hormone-dependent dimerization even when removed from the rest of the protein.
Moreover, fusion of EGFR/v-ErbB or Raf to other conditional dimerization systems (FKBP12 and derivatives, GyrB) gives rise to conditionally active forms of the cognate protein kinase that have been published by several other research groups (Farrar et al., 1996; Luo et al., 1996; Muthuswamy et al., 1999) .
The addition of estrogen analogs to cells expressing various protein kinase:ER fusion proteins leads to the rapid, post-translational activation of protein kinase activity (Samuels et al., 1993; McCubrey et al., 1998; McMahon, 2001 ). To determine if v-ErbB:ER was also (c) 1 mM 4HT for 24 h in phenol red free DMEM medium containing 5% CS FBS. In (d-f), 500 NIH-3T3/v-ErbB:ER cells were initially seeded in 60 mm plates and cultured for 2 weeks in phenol red free medium containing 5% CS FBS and 1 mM b-estradiol to allow focus formation to occur. After focus formation became visible, the cells were treated with: (d) 0.25% (v/v) DMSO, (e) 5 mM U0126 or (f) 5 mM LY294002 for 48 h in medium containing 1 mM b-estradiol. Cells were photographed using a Nikon TMS microscope at Â 100 magnification rapidly activated upon hormone addition, NIH-3T3 cells expressing v-ErbB:ER were treated with b-estradiol for different periods of time. Cell extracts were prepared and the tyrosine phosphorylation of v-ErbB:ER and other cellular proteins assessed by immunoprecipitation and Western blotting. The addition of b-estradiol led to rapid tyrosine phosphorylation of v-ErbB:ER that was detected B60 min after hormone addition (panel b). This is consistent with the rapid activation of a number of other protein kinase:ER fusion proteins such as DRaf-1:ER. Analysis of whole-cell extracts revealed a modest stimulation of tyrosine phosphorylation in response to v-ErbB:ER activation that is entirely consistent with the extent of tyrosine phosphorylation observed in NIH-3T3 cells transformed by constitutively active v-ErbB (panel c) McMahon et al., 1991) . These data clearly indicate that the vErbB:ER chimera is hormone dependent for biochemical activation of protein tyrosine kinase activity and phosphorylation, as well as for oncogenic cell transformation.
Conditional v-ErbB:ER expression abrogates the cytokine dependence of hematopoietic cells
Hematopoietic cell lines have been isolated that require IL-3 or in some cases GM-CSF for survival (Dexter et al., 1980; McKearn et al., 1985; Kitamura et al., 1989; Shelton et al., 2004a-c) . Hence, IL-3 and GM-CSF are sometimes referred to as survival factors. The human TF-1 line is a cytokine-dependent (IL-3, GM-CSF) line isolated from a patient with erythroleukemia (Kitamura et al., 1989) . FDC-P1 is an IL-3/GM-CSF-dependent cell line recovered from the bone marrow of normal DBA/2 mice and is representative of early hematopoietic precursor cells (Dexter et al., 1980) . The IL-3-dependent FL5.12 cell line was isolated from fetal liver and resembles early hematopoietic cells (McKearn et al., 1985) . Either IL-3 or GM-CSF is required for the survival of these cell lines and their removal results in apoptosis, programmed cell death. While these cell lines proliferate continuously in culture as long as IL-3 or GM-CSF is provided, they are non-tumorigenic upon injection into immunocompromised mice (McCubrey et al., 1989) . The loss of cytokine dependency by hematopoietic cells is an important factor in the development of leukemias. Spontaneous factor-independent cells are rarely recovered from these cell lines, which makes them attractive model systems to analyse the effects various genes have on signal transduction and leukemogenesis (McCubrey et al., 1989 (McCubrey et al., , 1993 . The following studies sought to investigate the effects of the conditional v-ErbB:ER oncoprotein on the cytokine dependence of hematopoietic cells. The human TF-1 and murine FDC-P1 and FL5.12 cells were infected with the retroviral vector encoding the v-ErbB:ER oncogene. Some cells were infected with a retroviral vector encoding the BCR-ABL-activated oncoprotein or an empty retroviral vector (LNL6) as positive and negative controls, respectively. As an additional negative control, cells were mock infected (Table 1) .
At 2 days post-infection, the cells were plated in medium containing cytokines (IL-3 or GM-CSF) and G418, in medium containing G418 and b-estradiol or in medium containing G418 but lacking cytokines and bestradiol. After a mock infection, no colonies growing in the presence of cytokine and G418 or b-estradiol and G418 were recovered, indicating that the G418 concentration was sufficient to kill uninfected cells (Table 1) . After infection of these cells with the empty pLNL6 retroviral vector, colonies were observed growing in the presence of cytokines and G418 (Table 1) . However, no clones were isolated when the LNL6-infected cells were plated in medium lacking cytokines, indicating that infection with the retroviral vector was not sufficient to isolate cytokine-independent cells.
As expected, when the cells were infected with the v-ErbB:ER retrovirus, colonies growing in the presence of cytokine and G418 were readily observed. Moreover, v-ErbB:ER abrogated the cytokine dependence of these hematopoietic cells, as cells growing in the presence of b-estradiol and G418 were recovered. Furthermore, v-ErbB:ER-responsive cells were readily recovered from the cytokine and G418 selected cells at an efficiency approaching 1, as determined by limiting dilution analysis, indicating that the v-ErbB:ER oncogene readily abrogated the cytokine dependence of these cells (data not presented). The activation of the conditional v-ErbB:ER oncogene was required for the isolation of cytokine-independent cells as no colonies were recovered when the cells were plated in the absence of b-estradiol.
The effects of the BCR-ABL-activated tyrosine kinase on the cytokine dependence of these cells were determined as a control. BCR-ABL abrogated the cytokine dependence of all three cell lines. However, unlike the v-ErbB:ER-infected cells, BCR-ABL-transformed cells were recovered in the absence of bestradiol.
Conditional growth of v-ErbB:ER-transformed cells
The growth characteristics of the v-ErbB:ER-responsive hematopoietic cells were examined (Figure 4) . The vErbB:ER-responsive FDC-P1, FL5.12 and TF-1 cells proliferated in response to cytokines or b-estradiol. However, the cells did not proliferate in the absence of cytokines or b-estradiol. Thus, the v-ErbB:ER protein conditionally abrogated the cytokine dependence of hematopoietic cells.
v-ErbB:ER activates the Raf/MEK/ERK and PI3K/Akt pathways
The Raf/MEK/ERK and PI3K/Akt pathways are central in the transmission of proliferative and antiapoptotic effects. To determine whether v-ErbB:ER induced the activation of the Raf/MEK/ERK and PI3K/Akt pathways, FL/v-ErbB:ER cells were deprived of b-estradiol for 24 h to synchronize the cells, and then treated with IL-3 or 4HT for varying periods of time. The presence of activated forms of the MEK1, ERK and Akt were examined by Western blotting (Figure 5 ). Activated MEK, ERK and Akt were detected with phospho-specific antibodies (Ab) 15 min after IL-3 treatment. Activated forms of MEK and ERK were detected 30 min after 4HT stimulation. Activated Akt was detected 2 h after 4HT stimulation.
The specificity of induction of these molecules was also examined by pretreatment of the cells with EGF-R, MEK and PI3K inhibitors. To determine whether the EGF-R inhibitor suppressed ERK and Akt activation, the FL/v-ErbB:ER cells were deprived of 4HT for 24 h, and then pretreated with the EGF-R inhibitor (4 mM, AG1478) for 1 h before the addition of either IL-3 or 4HT, and then protein lysates were prepared from samples isolated at different time points after stimulation ( Figure 5) . Treatment with the EGF-R inhibitor suppressed MEK, ERK and Akt activation in response to 4HT treatment but not IL-3.
Treatment of FL/v-ErbB:ER cells with the MEK inhibitor U0126 suppressed the appearance of activated forms of ERK after either IL-3 or 4HT treatment. Interestingly, pre-treatment with the MEK inhibitor U0126 did not suppress the appearance of activated forms of MEK after either IL-3 or 4HT treatment. U0126 has been reported to suppress MEK activity and not MEK activation (Favata et al., 1998) . Pretreatment of FL/v-ErbB:ER cells with U0126 did not suppress the activation of Akt in response to either IL-3 or 4HT treatment.
The effects of inhibition of the PI3K pathway were also examined. Pre-treatment of FL/v-ErbB:ER cells In summary, the EGF-R inhibitor suppressed MEK, ERK and Akt activation in response to v-ErbB:ER activation, but not after IL-3 stimulation. In contrast the MEK and PI3K inhibitors suppressed both ERK and Akt activation in response to either IL-3 or v-ErbB:ER activation.
v-Erb-B:ER prevents apoptosis
The effects of v-ErbB:ER expression on the prevention of apoptosis were examined (Figure 6 ). In these experiments, the cytokine-dependent parental FDC-P1 and factor-independent FD/BCR-ABL cells were used as controls. When FDC-P1 or FD/v-ErbB:ER cells were cultured in the absence of IL-3 or 4HT for 48 h, 19 and 22% of the cells registered as viable (panels a and d, bottom left quadrants) and 80 and 70% of the cells registered as apoptotic (sum of annexin-positive cells in upper left and right quadrants in panels a and d). In contrast, when the cells were cultured in the presence of IL-3 for 48 h, 85 and 60% of the cells were viable (panels b and e). When these cells were cultured in medium containing 4HT, approximately 18 and 61% of the cells were viable and 81 and 34% of the cells were apoptotic (panels c and f). Thus, the expression of the activated v-ErbB:ER oncoprotein hindered apoptosis in the FD/v-ErbB:ER cells, but as expected, 4HT did not prevent apoptosis in FDC-P1 cells. In contrast, cells transformed with the BCR-ABL oncoprotein were viable in the absence and presence of IL-3 (panels g-i), demonstrating the effects of constitutive BCR-ABL oncoprotein expression on the prevention of apoptosis.
Effects of EGFR, MEK and PI3K inhibitors on the induction of apoptosis
Previously, it was shown that v-ErbB:ER induced MEK, ERK and Akt activation, and pretreatment with an EGF-R inhibitor inhibited the appearance of activated forms of MEK, ERK and Akt ( Figure 5 ). To determine the consequences EGF-R, MEK and PI3K inhibition on the induction of apoptosis, FDC-P1 and FD/v-ErbB:ER cells were treated with EGF-R, MEK and PI3K inhibitors and the extent of apoptosis was determined by annexin V/PI binding assays. As controls for the specificity of these inhibitors, the effects of AG1478, U0126 and LY294002 on cells transformed by BCR-ABL and DRaf-1:ER (Hoyle et al., 2000) were also determined. The percentage of viable cells vs inhibitor concentration is plotted graphically in Figure 7 . FDC-P1 cells were grown in medium (RPMI þ 10% FBS) supplemented with IL-3, FD/ BCR-ABL were cultured in the absence of additional supplements and FD/v-ErbB:ER and FD/DRaf-1:ER were cultured in medium supplemented with 4HT.
At concentrations approaching the IC 50 for AG1478 (3 nM), apoptosis was observed in the FD/v-ErbB:ER, but not in the FDC-P1 parental cell line (panel a) or cells transformed by either BCR-ABL or activated Raf-1 Figure 5 v-ERBB:ER activates MEK, ERK and AKT phosphorylation. FL/v-ErbB:ER cells were cultured in the absence of 4HT for 24 h in phenol red free RPMI 1640 containing 5% CS FBS to avoid estrogenic effects of phenol red and endogenous estrogens present in FBS. The cells were then treated with DMSO, 5 mM U0126, 5 mM LY294002, 4 mM AG1478 for 1 h and a portion of the cells were collected. Then, the cells were treated with either IL-3 or 500 nM 4HT for the indicated time points and the remaining protein lysates made. Western blots were performed with Ab, which recognized activation-specific and total proteins. This experiment was repeated three times and similar results were obtained. Similar results were observed with FD/v-ErbB:ER cells (panel b). Induction of apoptosis in FD/v-ErbB:ER cells was observed at as low as 400 pM AG1478. In contrast, apoptosis was only observed in FDC-P1, FD/BCR-ABL and FD/DRaf-1:ER cells when they were cultured in 40 mM AG1478. At concentrations approaching 5 mM, the MEK (panels c and d) and PI3K (panels e and f) inhibitors induced apoptosis in all cell lines; however, less apoptosis was observed in FD/BCR-ABL cells when they were treated with the MEK inhibitor.
The effects of the EGF-R inhibitor on apoptosis and DNA synthesis in FD/v-ErbB:ER cells were further examined (Figure 8 ). AG1478 induced apoptosis and inhibited DNA synthesis when the FD/v-ErbB:ER cells were cultured in 4HT-containing medium, which activated the v-ErbB:ER, but not when they were cultured in response to IL-3 (Figure 8 ). Even when the FD/vErbB:ER cells were cultured in the presence of both IL-3 and 4HT, the EGF-R inhibitor did not induce apoptosis or inhibit DNA synthesis, indicating that this EGF-R inhibitor did not suppress cytokine-mediated prevention of apoptosis or DNA synthesis when the cells were grown in the presence of an activated v-ErbB:ER protein (data not presented). Thus, this inhibitor targeted Erb-B-mediated growth but had little effects on normal cytokine-mediated proliferation.
Discussion
One of the goals of this research was to investigate the effects of conditional ErbB kinase activity upon the morphological transformation of NIH-3T3 cells and the abrogation of cytokine-dependence of hematopoietic cells. The novel v-ErbB:ER conditional oncogene used in these studies conditionally transformed NIH-3T3 cells and abrogated the cytokine-dependence of hematopoietic cells. FDC-P1, FL5.12 and TF-1 hematopoietic cells, which grew in response to v-ErbB:ER in the absence of exogenous cytokines were readily and efficiently isolated. Cell proliferation and prevention of apoptosis were determined to be dependent on v-ErbB, PI3K/Akt and Raf/MEK/ERK activities as treatment of the hematopoietic cells with inhibitors to these pathways prevented proliferation and promoted apoptosis. v-Erb-B:ER did not appear to induce autocrine cytokines, which exerted effects on DNA synthesis or ERK or Akt activation in either FDC-P1 or FL5.12 cells (data not presented).
The v-ErbB:ER-and BCR-ABL-activated tyrosine kinases were able to transform efficiently FL5.12 hematopoietic cells to cytokine independence. This may result from their ability to induce both the Raf/MEK/ERK and PI3K/Akt, as well as other downstream pathways. Recently, it was shown that overexpression of activated Raf or Akt by themselves did not abrogate the cytokine dependence of FL5.12 cells ; however, upon activation of both pathways, a synergistic effect on abrogation of cytokine dependence was observed. Thus, while FDC-P1 cells are transformed by activated Raf (Hoyle et al., 2000) , FL5.12 cells require activated Raf and Akt to become factor independent . In this study, we have demonstrated that v-ErbB:ER, which can activate both the Raf/MEK/ERK and PI3K/Akt pathways, can also readily abrogate the cytokine dependence of FL5.12 cells. (LY294002) inhibitors, and the extent of apoptosis was determined by annexin V/PI binding as described in Figure 6 . (b, d and f) FD/BCR-ABL cells in medium with no additional supplement (solid diamonds E) and FD/DRaf-1:ER cells in 4HT (solid circles, ) were cultured for 2 days in the presence of different concentrations of EGF-R (AG1478), MEK (U0126) and PI3K (LY294002) inhibitors, and the extent of apoptosis was determined by annexin V/PI binding as described in Figure 6 . These experiments were performed four to six times and averaged together. The statistically significant differences between the FD/v-ErbB:ER and FDC-P1 cells treated with the AG1478 inhibitor are indicated by **Po0.01, which were determined by a Student's t-test. The statistically significant differences between the FD/BCR-ABL and FD/DRaf-1:ER cells treated with the AG1478 inhibitor are indicated by **Po0.01, which were determined by a Student's t-test v-ErbB:ER activated downstream MEK, ERK and Akt. The EGF-R inhibitor AG1472 inhibited MEK, ERK and Akt activation when the cells were grown in response to v-ErbB:ER, but not when they were grown in response to IL-3. Furthermore, AG1478 induced apoptosis when the cells were grown in response to vErbB:ER, but not when they were grown in response to either IL-3 or both IL-3 and v-ErbB:ER (presence of both IL-3 and 4HT in the culture medium). Thus, IL-3 can induce downstream signal transduction pathways, which promote proliferation in the presence of an activated v-ErbB:ER and EGF-R inhibitor.
The MEK inhibitor U0126 inhibited the appearance of activated forms of ERK when the cells were cultured in either 4HT-or IL-3-containing medium. While the MEK inhibitor U0126 inhibited the appearance of activated ERK, it did not inhibit the appearance of activated MEK that was detected with the phosphospecific MEK1 Ab purchased from Cell Signaling. Similar results have been observed in cells that grow in response to activated Raf and Akt. Thus, our results indicate that U0126 does not prevent the detection of phosphorylated forms of MEK1 by the phospho-specific MEK1 Ab, but it does block downstream ERK activation, as activated forms of ERK1 and ERK2 were not detected. Indeed similar results with 40126 not blocking MEK phosphorylation but having an effect on ERK phosphorylation have been reported (Ahn et al., 2001) . Some other studies with this inhibitor have indicated that U0126 blocks MEK1 activation (Davies et al., 2000) . However, the major difference lies in how activation of MEK1 was detected. In the study by Davies et al., an in vitro kinase assay was performed with immunoprecipitated proteins, whereas our studies have used a phospho-specific Ab, which has only recently become commercially available. In contrast, when the FL/v-ErbB:ER cells were grown in response to v-ErbB:ER, the EGF-R inhibitor blocked both MEK and ERK activation, indicating that the EGF-R inhibitor blocked EGF-R-mediated MEK activation.
The PI3K inhibitor LY294002 inhibited the appearance of activated forms of Akt. This occurred when the cells were grown in response to either 4HT or IL-3. Thus, both the MEK and PI3K inhibitors had effects on cells when they were grown in response to either IL-3 or 4HT. Although MEK and PI3K inhibitors may eventually prove to be effective in inducing apoptosis of malignant clones, they may also effect the growth of normal cells which rely on functional MEK and PI3K activity for proliferation.
The v-ErbB:ER-transformed hematopoietic cells were very sensitive to the EGF-R inhibitor AG1478 when they were grown in response to v-ErbB:ER. In contrast, cytokine-dependent FDC-P1 cells or FD/v-ErbB:ER cells grown in response to IL-3 were 100-to 1000-fold less sensitive to the EGF-R inhibitor AG1478. Thus in this system, the v-ErbB:ER-responsive cells were very sensitive to the EGF-R inhibitor. Humans with lung cancers expressing mutated EGF-R are in many cases more responsive to inhibition of EGF-R using Iressa. In other transformed human cells, the situation is more complex as there may be multiple gene mutations, which are necessary for malignant growth. Furthermore, these studies point to the need to identify the precise mutation(s) that allows the malignant clones to proliferate in the absence of the previously required survival signals. Targeting these oncogenic proteins may prove more effective in therapy.
Materials and methods
for expression in mammalian cells McMahon et al., 1991) .
Retroviral infection of cells
The neomycin-resistant (neo r ) pLNCv-ErbB:ER retrovirus was used in this study. As a control for some experiments, some cells were infected with a retrovirus encoding BCR-ABL (Clark et al., 1988) .
NIH-3T3, TF-1, FDC-P1 and FL5.12 cells were infected with viral stocks as described (Samuels et al., 1993; McCubrey et al., 1998) . Neo r NIH-3T3 cells were isolated by selection in medium containing 500 mg/ml G418. Neo r TF-1, FDC-P1 or FL5.12 cells were isolated by selection in medium containing 2 mg/ml G418 (Sigma) in the presence of either cytokine (GM-CSF or IL-3) or b-estradiol as described (McCubrey et al., 1998) . The cells used for the following study were selected in cytokine and G418. They were determined to be v-ErbB:ER responsive by limiting dilution analysis by comparing their plating efficiency in the presence of b-estradiol or IL-3. The nomenclature of the v-ErbB:ER-infected cells is TF/vErbB:ER, FD/v-ErbB:ER and FL/v-ErbB:ER. The nomenclature of BCR-ABL-infected cells is FD/BCR-ABL, FL/ BCR-ABL and TF/BCR-ABL. FD/DRaf-1:ER cells infected with the conditionally active DRaf-1:ER gene have been described previously (Hoyle et al., 2000) .
Preparation of cell extracts and analysis by Western blotting
Protein extracts and Western immunoblotting with phosphospecific and control Ab was performed as described . aER Ab was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Phospho-specific MEK, ERK, Akt Ab as well as Ab, which recognize total MEK, ERK and Akt, were purchased from Cell Signaling (Beverly, MA, USA). The a-phosphotyrosine monoclonal 4G10 Ab was purchased from Upstate Bioltechnology (Lake Placid, NY, USA).
Apoptosis assays using annexin V/PI
Annexin V/PI binding experiments were preformed as described .
